Shots: The US FDA’s approval is based on five P-II & P-III studies assessing MenQuadfi vs licensed quadrivalent meningococcal in ~5000 people aged ≥2yrs. Four studies evaluated MenQuadfi in meningococcal-naïve person and the other study evaluated MenQuadfi in persons prior to immunized with a quadrivalent meningococcal vaccine Meningococcal-naïve person showed 55.4%–97.2% vaccine induced response 30 […]Read More
Tags : Meningococcal
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Regeneron
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US